2251806-70-7

Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2]. IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets[2]. IRL752 (3.7-100 μmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2].

[1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease. [2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419.